Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.31% | 6.61% | -0.68% | 19.05% | 2.56% |
| Total Depreciation and Amortization | 32.53% | -1.57% | -14.38% | 0.45% | -1.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.12% | -3.68% | 4.30% | -17.57% | -5.81% |
| Change in Net Operating Assets | 1,459.86% | -83.78% | -105.04% | 621.40% | 141.41% |
| Cash from Operations | 304.69% | -3.55% | -168.52% | 289.99% | 21.78% |
| Capital Expenditure | -266.67% | 33.33% | 57.14% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -266.67% | 33.33% | 57.14% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 66.67% | 99.37% | -98.70% |
| Issuance of Common Stock | -41.09% | 204,950.00% | -99.98% | 365.74% | 7,877.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -41.09% | 273,500.00% | -100.01% | 2,000.94% | 158.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 666.82% | 56.44% | -134.23% | 518.67% | 36.60% |